Monocyte activation test
Commonly used acronym: MAT
Scope of the method
- Human health
- Regulatory use - Routine production
- In vitro - Ex vivo
- Human derived cells / tissues / organs
- Pyrogen test
- alternative to rabbit pyrogen test
- european pharmacopoeia
- endotoxins and non-endotoxin pyrogens
- quality control of injectable medicines
The monocyte-activation test (MAT) is used to detect or quantify substances that activate human monocytes or monocytic cells to release endogenous mediators such as pro-inflammatory cytokines, for example tumour necrosis factor alpha (TNFα), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6). These cytokines have a role in fever pathogenesis. Consequently, the MAT will detect the presence of pyrogens (endotoxins on non-endotoxin pyrogens) in the test sample. The MAT is suitable, after a product-specific validation, as a replacement for the rabbit pyrogen test (see European pharmacopoeia chapter 2.6.30). Although 3 methods (quantitative test, semi-quantitative test or reference lot comparison test) are described in the Ph. Eur.
- Biosafety cabinet ;
- CO2-incubator ;
- ELISA plate reader.
- Still in development
- History of use
Pros, cons & Future potential
- No rabbits ;
- ex-vivo test.
Proper storage of whole human blood (store only in nitrogen tank, not at minus 80°C).
References, associated documents and other information
- User Manual of the PyroDetect System Monocyte-Activation Test (MAT) from Merck ;
- Monocyte Activation Test guideline from European Pharmacopoeia.
Contact personCeline Vanhee
Chemical and physical health risks
Medicines and health products